Switzerland-based drugmaker Actelion has confirmed the initiation of preliminary discussions with US-based ZS Pharma over a potential transaction.

ZS Pharma has also confirmed participation in discussions with Actelion which may or may not lead to any transaction.

Bloomberg reported sources familiar with the matter as saying that Actelion made an offer last month to buy ZS Pharma in a deal worth $2.5bn.

"The acquisition will enable Actelion to expand its treatments for pulmonary arterial hypertension."

In a corporate statement, ZS Pharma said it will not ‘disclose any developments unless and until it otherwise deems further disclosure is appropriate or required’.

According to Actelion, the acquisition will enable the company to expand its treatments for pulmonary arterial hypertension, while maximising its market value.

Biopharmaceutical company ZS Pharma has offices in Redwood City, California and Coppell, Texas. Its lead therapeutic candidate ZS-9 (sodium zirconium cyclosilicate) is an investigational treatment for hyperkalemia.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Actelion focuses on the discovery, development and commercialisition of new drugs for diseases with significant unmet medical needs, such as pulmonary arterial hypertension.

Its portfolio of PAH treatments comprises the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications.

In June, reports emerged that Ireland’s Shire made an informal approach to Actelion for a £12.4bn takeover.